Femasys inc. secures additional financing with strategic investment from investors led by pharmacyte biotech

- $6.85 million upfront investment provides $23 million total cash runway into second half 2025 - - financing allows for focused commercial team to bring femasys' infertility-related products to women in the u.s. - - additional financing supports the advancement of femasys' lead product candidate, fembloc ® for permanent birth control, to initial clinical data readout - atlanta, nov. 15, 2023 (globe newswire) -- femasys inc. (nasdaq: femy), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today announced a strategic upfront investment of $6.85 million by public biotech company, pharmacyte biotech, inc. (nasdaq: pmcb) and other healthcare investors. femasys is creating accessible innovative options for women, as exemplified by its lead product candidate, fembloc, in late-stage clinical development for permanent birth control and fda-cleared product, femaseed ® for infertility treatment (also approved in canada).
FEMY Ratings Summary
FEMY Quant Ranking